Table 2: Patients characteristics at baseline and disease scores comparison.
Variables (n = 74) | |||
Age, years (mean ± SD) | 49.7 ± 15.5 | DAS28 scores (mean ± SD) | |
Female gender, n (%) | 63 (85.1) | Using 3 variables (TJC, SJC, ESR/CRP) | |
Geographical location, n (%) | DAS28-ESR-3 | 5.5 ± 0.7 | |
Guinea | 64 (86.5) | DAS28-CRP-3 | 4.9 ± 0.6 |
Cameroon | 10 (13.5) | Paired t-test, p value* | < 0.0001 |
Standard (TJC, SJC, ESR/CRP, VAS) | |||
Disease duration, months (median, IQR)§ | 36 (12-90) | DAS28-ESR | 5.8 ± 0.8 |
RF-positive, n (%)¶ | 51 (78.5) | DAS28-CRP | 5.3 ± 0.7 |
ACPA-positive, n (%)¶ | 31 (81.6) | Paired t-test, p value* | < 0.0001 |
TJC-28 (mean ± SD) | 11.0 ± 4.1 | Tamhane, et al. and DAS28-ESR | |
SJC-28 (mean ± SD) | 3.5 ± 1.9 | DAS28-ESR | 5.8 ± 0.8 |
Patient global assessment (VAS, 0 -100 mm) | 64.4 ± 19.1 | Adjusted† DAS28-CRP | 5.9 ± 0.6 |
ESR, mm/h (median, IQR) | 45.0 (32.0-68.0) | Paired t-test, p value* | 0.7563 |
CRP, mg/dl (median, IQR) | 20.5 (12.0-33.4) | Study data-specific and DAS28-ESR | |
DAS28-ESR | 5.8 ± 0.8 | ||
Adjusted† DAS28-CRP | 5.8 ± 0.6 | ||
Paired t-test, p value* | 0.9992 |
*: p value for comparing means; †: Adjusted for age and sex; §: Data were missing for 42 patients from Senegal; ¶: Data were missing for 9 and 38 patients respectively for RF and ACPA; DAS: Disease Activity Score; ESR: Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein; TJC: 28 Tender Joint Count; SJC: 28 Swollen Joint Count; VAS: Visual Analog Scale, self-assessed patient global assessment of disease activity on a VAS of 0 to 100 mm; SD: Standard Deviation; IQR: Inter Quartile Range.